X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DR. REDDYS LAB - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DR. REDDYS LAB PFIZER/
DR. REDDYS LAB
 
P/E (TTM) x 31.4 30.5 102.9% View Chart
P/BV x 5.0 3.0 166.9% View Chart
Dividend Yield % 0.6 0.9 71.8%  

Financials

 PFIZER   DR. REDDYS LAB
EQUITY SHARE DATA
    PFIZER
Mar-16
DR. REDDYS LAB
Mar-17
PFIZER/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,7243,397 80.2%   
Low Rs1,6112,560 62.9%   
Sales per share (Unadj.) Rs440.9856.5 51.5%  
Earnings per share (Unadj.) Rs48.778.0 62.5%  
Cash flow per share (Unadj.) Rs75.8139.9 54.2%  
Dividends per share (Unadj.) Rs15.0020.00 75.0%  
Dividend yield (eoy) %0.70.7 103.1%  
Book value per share (Unadj.) Rs462.9739.8 62.6%  
Shares outstanding (eoy) m45.75165.74 27.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.93.5 141.4%   
Avg P/E ratio x44.538.2 116.5%  
P/CF ratio (eoy) x28.621.3 134.4%  
Price / Book Value ratio x4.74.0 116.3%  
Dividend payout %30.825.7 120.1%   
Avg Mkt Cap Rs m99,163493,632 20.1%   
No. of employees `0002.922.7 12.7%   
Total wages/salary Rs m2,75831,068 8.9%   
Avg. sales/employee Rs Th6,981.76,259.0 111.5%   
Avg. wages/employee Rs Th954.51,369.8 69.7%   
Avg. net profit/employee Rs Th771.1569.7 135.4%   
INCOME DATA
Net Sales Rs m20,170141,961 14.2%  
Other income Rs m8571,715 50.0%   
Total revenues Rs m21,028143,676 14.6%   
Gross profit Rs m4,31024,722 17.4%  
Depreciation Rs m1,23910,266 12.1%   
Interest Rs m5634 0.8%   
Profit before tax Rs m3,92315,537 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7942,965 60.5%   
Profit after tax Rs m2,22812,921 17.2%  
Gross profit margin %21.417.4 122.7%  
Effective tax rate %45.719.1 239.7%   
Net profit margin %11.09.1 121.3%  
BALANCE SHEET DATA
Current assets Rs m16,29996,837 16.8%   
Current liabilities Rs m7,59484,199 9.0%   
Net working cap to sales %43.28.9 484.8%  
Current ratio x2.11.2 186.6%  
Inventory Days Days6573 89.0%  
Debtors Days Days2698 26.4%  
Net fixed assets Rs m8,622102,552 8.4%   
Share capital Rs m458829 55.2%   
"Free" reserves Rs m20,722121,792 17.0%   
Net worth Rs m21,180122,621 17.3%   
Long term debt Rs m255,449 0.5%   
Total assets Rs m29,137218,165 13.4%  
Interest coverage x755.525.5 2,961.9%   
Debt to equity ratio x00 2.7%  
Sales to assets ratio x0.70.7 106.4%   
Return on assets %7.76.2 123.3%  
Return on equity %10.510.5 99.8%  
Return on capital %19.012.9 147.2%  
Exports to sales %0.154.6 0.1%   
Imports to sales %17.59.4 186.9%   
Exports (fob) Rs m1277,520 0.0%   
Imports (cif) Rs m3,52613,274 26.6%   
Fx inflow Rs m5281,670 0.1%   
Fx outflow Rs m14026,355 0.5%   
Net fx Rs m-8855,315 -0.2%   
CASH FLOW
From Operations Rs m3,43621,444 16.0%  
From Investments Rs m-6,991-18,404 38.0%  
From Financial Activity Rs m-619-3,692 16.8%  
Net Cashflow Rs m-4,174-1,144 364.8%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 5.4 138.9%  
FIIs % 4.9 35.3 13.9%  
ADR/GDR % 0.0 18.5 -  
Free float % 23.7 15.3 154.9%  
Shareholders   85,207 75,885 112.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare PFIZER With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 16, 2018 (Close)

TRACK PFIZER

PFIZER - FULFORD INDIA COMPARISON

COMPARE PFIZER WITH

MARKET STATS